Clinical Trial Detail

NCT ID NCT02155920
Title Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Texas Southwestern Medical Center
Indications

pediatric ependymoma

Therapies

Everolimus

Age Groups: child

No variant requirements are available.